Recent Finacing
Recent Raise
Refuge Biotechnologies develops programmed cell therapeutics that use a receptor‑dCas platform—dCas-based CRISPR activation and interference—to sense inputs and produce therapeutic proteins inside patients.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Refuge Biotechnologies.
